Authors: Loffroy, Romaric; Guiu, Boris; Cercueil, Jean-Pierre; Krause, Denis

Source: Current Vascular Pharmacology, Volume 7, Number 2, April 2009 , pp. 250-263(14)

Publisher: Bentham Science Publishers

Abstract:

Vascular embolisation agents are particles or fluids that can be released into the bloodstream through a catheter to mechanically and/or biologically occlude the target vessel, either temporarily or permanently. This definition excludes vessel-blocking agents or devices such as balloons and coils, which are positioned at the target site, as opposed to released in the bloodstream. Vascular embolisation agents are available as solids, liquids and suspensions. Careful selection of the agent based on the size and calibre of the target vessel ensures that the occlusion is confined to the desired site. In this review, we discuss the 2 main categories of embolisation agents: particles (either non-spherical or microspherical), which are the most widely used; and liquids (glues, gels, sclerosing agents and viscous emulsions). For each agent, we review the characteristics, mechanisms of action, main indications and modalities of use, advantages and drawbacks. The use of embolisation in clinical practice requires a thorough understanding of the behaviour (rheology and vascular topology) and biocompatibility of each agent. To improve the accuracy of targeting, we need new, more sophisticated, bioactive agents, which are being developed.

Keywords: Interventional radiology; endovascular embolisation; occluding agents; resorbable embolic material; particles; surgical glue

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157016109787455617

Publication date: 2009-04-01

More about this publication?

• Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials.
  
  Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units). Current Vascular Pharmacology will publish reviews to update all those concerned with the treatment of vascular disease. For example, reviews commenting on recently published trials or new drugs will be included. In addition to clinically relevant topics we will consider 'research-based' reviews dealing with future developments and potential drug targets. Therefore, another function of Current Vascular Pharmacology is to bridge the gap between clinical practice and ongoing research.
  
  Debates will also be encouraged in the correspondence section of this journal.

Related content

• In this: publication
• By this: publisher
• In this Subject: Cardiovascular Medicine ,  Pharmacology
• By this author: Loffroy, Romaric ;  Guiu, Boris ;  Cercueil, Jean-Pierre ;  Krause, Denis

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers